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Abstract
Introduction Although there is clear evidence for the seroto-
nergic regulation of descending control of pain in animals,
little direct evidence exists in humans. The majority of our
knowledge comes from the use of serotonin (5-HT)-modulat-
ing antidepressants as analgesics in the clinical management
of chronic pain.
Objectives Here, we have used an acute tryptophan depletion
(ATD) to manipulate 5-HT function and examine its effects of
ATD on heat pain threshold and tolerance, attentional manipu-
lation of nociceptive processing andmood in human volunteers.
Methods Fifteen healthy participants received both ATD and
balanced amino acid (BAL) drinks on two separate sessions in a
double-blind cross-over design. Pain threshold and tolerance
were determined 4 h post-drink via a heat thermode.
Additional attention, distraction and temperature discrimination
paradigmswere completed using a laser-induced heat pain stim-
ulus. Mood was assessed prior and throughout each session.
Results Our investigation reported that the ATD lowered plas-
ma TRP levels by 65.05 ± 7.29% and significantly reduced
pain threshold and tolerance in response to the heat thermode.
There was a direct correlation between the reduction in total
plasma TRP levels and reduction in thermode temperature. In
contrast, ATD showed no effect on laser-induced pain nor
significant impact of the distraction-induced analgesia on pain
perception but did reduce performance of the painful temper-
ature discrimination task. Importantly, all findings were inde-
pendent of any effects of ATD on mood.
Conclusion As far as we are aware, it is the first demonstra-
tion of 5-HT effects on pain perception which are not con-
founded by mood changes.
Keywords Serotonin . Tryptophan . Pain . Acute tryptophan
depletion (ATD)
Introduction
Pain is essential for avoiding damage and a vital learning
mechanism for survival. The processing of pain is not isolated
to one region of the brain and integrates information from a
number of regions which form the pain matrix (Vogt et al.
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1996; Legrain et al. 2011; Jones and Brown 2017; Denk et al.
2014). Hence, pain is considered to be the combination of
multiple factors such as stimulus intensity, emotional and con-
textual state and individual past experiences which contribute
to the expectation of pain. In contrast to acute pain, the devel-
opment of chronic pain, particularly neuropathic pain, is
regarded to be, in most cases, a maladaptive process providing
the sufferer with no benefits, whereas in chronic musculoskel-
etal pain, there may be a mixture of pains, some of which have
a protective function and others which are more maladaptive
(Jones and Brown 2017). There is a high prevalence of chron-
ic pain in the population and a limited choice of successful
treatments. A potential choice of treatment is the use of selec-
tive serotonin reuptake inhibitors (SSRIs) which increase se-
rotonin (5-HT) within the brain which are also a common
choice of antidepressant. There have been mixed results re-
ported from the use of SSRIs, and the mechanism of action on
pain processing is unclear (Jung et al. 1997; Jann and Slade
2007). Evidence for the specific role of 5-HT in the modula-
tion of pain processing arises mainly from animal studies.
Descending inhibitory serotonergic spinal-raphe projections
from the nucleus raphe magnus form an endogenous descend-
ing pain-modulating network, capable of concurrently medi-
ating both the facilitation and inhibition of nociceptive pro-
cessing (Basbaum and Fields 1984; Fields et al. 1991; Kwiat
and Basbaum 1992;Millan 2002;Wei et al. 2012). In addition,
ascending serotonergic pain pathways, projecting from the
midbrain dorsal-raphe nucleus to limbic and adjacent fore-
brain sites, control the attentional processing of nociception
(Boyle et al. 2008; Brown and Jones 2008; Kosofsky and
Molliver 1987; O’Hearn and Molliver 1984).
The development of chronic pain has been linked with the
so-called maladaptive neuroplastic changes in the brain which
result in pain sensitivity (Jensen et al. 2016; Petersen-Felix
and Curatolo 2002; Jones and Brown 2017; Apkarian et al.
2004; Baliki et al. 2008). A study by Nitsche et al. (2009)
reported a role of 5-HT in neuroplasticity and reported that
an acute increase of 5-HT in healthy subjects increased facil-
itatory plasticity. Therefore, 5-HT levels within the brain may
also have an effect on the abnormal neuroplastic changes as-
sociated with chronic pain.
In humans, the exact role of 5-HT as a modulator in the
perception of experimental or chronic pain remains unclear.
Some evidence for the role of 5-HT in the pathophysiology of
several human chronic pain disorders is based on the analgesic
properties of 5-HT-modulating antidepressants (Dharmshaktu
et al. 2012; Mika et al. 2013; Atkinson et al. 1999; Bomholt
et al. 2005; Lee and Chen 2010; McQuay and Moore 1997).
However, the precise mechanisms behind these analgesic ef-
fects have not been defined. It remains uncertain whether the
apparent analgesic effects of 5-HT-modulating drugs are a direct
consequence of increased availability of 5-HTor as a secondary
effect of mood changes. Current arguments favour the direct
effects of 5-HT, as analgesia generally occurs prior to any
changes in mood (Hegerl et al. 2012; McQuay et al. 1996). A
technique to experimentally investigate the action of 5-HT in
humans is via global depletion of its precursor tryptophan
(TRP) using a method known as acute TRP depletion (ATD).
Previously, research has shown how 5-HT levels can be
manipulated to investigate pain processing via the supplemen-
tation and depletion of its precursor TRP (Wang et al. 2009;
Carpenter et al. 1998; Chase et al. 2011). Previous findings
show that TRP supplementation improves both pain tolerance
and mood in healthy volunteers (Seltzer et al. 1982). In con-
trast, a study using ATD reported that there were no changes to
the cold pressor pain (Abbott et al. 1992). However, the study
discovered that morphine-induced analgesia was abolished by
ATD and, hence, highlighting the complex involvement of
serotonin in pain processing. Furthermore, the central process-
ing of the pain caused from irritable bowel syndrome (IBS) has
been further investigated using ATD research. A study showed
that ATD in healthy subjects resulted in network disruption
homologous to disruption seen in IBS sufferers with pain
(Labus et al. 2011). Therefore, we hypothesised that depletion
of TRP levels would result in the sensitisation of pain, which
would be the opposite of supplementation of TRP studies.
Whilst there is still debate on the involvement of mood
changes induced by the ATD (Benkelfat et al. 1994;
Delgado et al. 1990; Ellenbogen et al. 1999; Robinson and
Sahakian 2009), studies have successfully dissociated pain
andmood changes following serotonin and noradrenaline sup-
plementation in patients suffering from depression (Hegerl
et al. 2012). A large-scale meta-analysis of 5-HT depletion
studies has shown that mood is not affected within a healthy
volunteer cohort with no history of depression (Young 2013).
However, there is a slight negative change in mood within
participants with a family history of major depressive disorder
(MDD). Additionally, MDD sufferers in remission were re-
ported to have the greatest decrease in mood, and serotonin
depletion resulted in a relapse of MDD (Ruhé et al. 2007). As
evidence suggests that ATD does not alter mood in subjects
with no history of depression, for this study, we have excluded
subjects with a history of depression and monitored alterations
in mood throughout the study.
The role of 5-HT in pain perception is far from clearly
defined; however, the use of SSRIs in treating pain conditions
indicates that a low level of 5-HT may correlate with an in-
creased sensitivity to pain (Goesling et al. 2013; Cooper et al.
2017). Therefore, the aim of this research was to use ATD to
investigate the role of 5-HT in pain perception whilst
attempting to dissociate the effects from mood changes. The
study primarily investigated the participants’ threshold and
tolerance level of a heat thermode after the ATD and control
balanced (BAL) drink. An additional exploratory investiga-
tion used CO2 laser stimuli combined with an attention and
distraction paradigm to explore the role of 5-HT in the central
processing of pain perception. This study will provide further
insight into how we utilise drugs to modulate 5-HTsystems as
pain therapies, independent of mood manipulation, as well as
provide an insight into the attentional processing of pain in
chronic pain conditions, such as fibromyalgia (FM) and com-
plex regional pain syndrome (CRPS), which are associated




Twenty healthy volunteers gave informed consent to partici-
pate in the study. Prior to study entry, a psychological assess-
ment determined volunteer suitability. The exclusion criteria
for recruitment included a history of depression, neurological
or psychiatric illness (assessed using the research version of
the SCID: Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders, fourth edition;
DSM-IV; First et al. 2002), or having a first-degree relative
with a history of depression. Further exclusion criteria
consisted of recreational drug or excessive caffeine use,
smokers and females with unpredictable menstrual cycles.
Additional criteria for female volunteers controlled for mood,
hormonal changes and pain sensitivity during their menstrual
cycle (Menkes et al. 1994). A local research ethics committee
approved the study (04/Q1407/286) and all participants gave
written informed consent.
Although 20 volunteers participated in the study, two were
excluded due to high HAD scores and three females were
excluded due to the phase of their cycle (recruited prior to
additional exclusion factors being enforced) Therefore, statis-
tical analysis reports the data of 15 volunteers (6 males).
Acute tryptophan depletion
TRP availability is the principal rate-limiting step in the 5-HT
biosynthetic pathway (Ruddick et al. 2006). In humans, low-
ering central serotonergic activity by ATD is accomplished by
consuming a TRP-free amino acid drink, which results in a
substantial decline in plasma TRP levels (~70%), with peak
depletion occurring approximately 4–6 h later (Moore et al.
2000). For this study, we used an ATDmixture and a balanced
control mixture (BAL) which contained all amino acids. The
compositions of the drinks were in replication of the methods
used in Moore et al. (2000).
Prior to testing days, the participants were required to under-
take a low-protein, caffeine-free, alcohol-free diet and fast from
midnight. The participants were reminded via an email 2 days
prior to each of their visits to ensure that they followed the pre-
study instructions. In addition to this, the researcher verified that
the participants complied with dietary instructions. Participants
arrived at 9:00 am on testing day and were randomly assigned a
150-ml amino-acid drink. Due to lower body mass, females
received 80% of the amino-acid cocktail. The time of this con-
sumption was classed as time point 0 h, following which vol-
unteers were exposed to a neutral environment (access to books
and videos free from emotional content).
Procedure
Participants were asked to complete three visits (one screening
session and two experimental sessions). The experimental ses-
sions (visits 2 and 3) were each separated by at least 2 weeks
for assessment of sensitivity to laser stimulation. This was
increased to 4 weeks for female volunteers, allowing both
experimental visits to coincide with the same phase of their
menstrual cycle (i.e. if their first session occurred during the
luteal phase of their cycle, they would return for the second
session in the same phase), which controlled for pain and
mood changes, associated with luteal phase dysphoric disor-
der (Menkes et al. 1994) and diminished serotonergic re-
sponses during the luteal phase of the menstrual cycle
(Warner et al. 1991).
During experimental visits 2 and 3, paradigms A and B
were assessed to investigate pain processing. Volunteers ad-
hered to the aforementioned diet and consumed either an ATD
drink or BAL drink consistent with the double-blind cross-
over design of the experiment.
Visit 1—screening
The screening visit included assessments of participant suitabil-
ity, training on experimental procedures and familiarisation with
the rating scales to minimise variability between visits due to
anxiety or task learning. Permission was obtained to test a urine
sample for recreational and illegal drugs. No ATD was carried
out during the screening visit, and participants organised visits 2
and 3 for the forthcoming weeks.
Visits 2 and 3—ATD pain investigation
Paradigm A Pain threshold and tolerance were assessed at
time points +4 and +6 h, measured using a Marstock heat
thermode (THERMOTEST, Somedic Production AB, 19205
Sollentuna, Sweden) applied to the dorsum of the right fore-
arm. To measure the pain threshold, the thermode temperature
was adjusted from baseline (32 °C), using the multiple stair-
case method as previously described (Gracely et al. 1988),
until a sensation of pain was perceived (‘pain threshold’).
Subsequently, the temperature was further increased from
the level established as ‘pain threshold’, until the pain became
unbearable and ‘pain tolerance’ was recorded (maximum
temp 52 °C).
Paradigm B During paradigm B, pain was administered
using a carbon dioxide (CO2) laser which is a technique con-
sistent with similar published data from our group (Kulkarni
et al. 2005; Boyle et al. 2008). The rapid nature of the laser
stimulus means that it is ideal for observing attentional ma-
nipulation. The CO2 laser delivered radiant heat stimuli (beam
15 mm diameter, pulse 150 ms duration) to the dorsum of the
right forearm. To prevent nociceptor sensitisation, the location
of successive stimuli was moved around a 3 × 5-cm stimula-
tion site on the dorsal surface of the forearm. The position of
the stimulation site was identical for each experimental ses-
sion. Throughout the study, volunteers wore protective gog-
gles and earplugs to mask acoustic interference from the laser
apparatus.
Initial psychophysics assessment determined the energy
level required to elicit a moderately painful stimulus. An 11-
point numerical scale was used to report pain perception (0–
10; 0 = no sensation, 4 = just painful, 6 = moderately painful
and 10 = unbearable pain). The main task of paradigm B
included two variations: attention and distraction which are
outlined below. Both variations were delivered in a two-
block design of 30 laser stimuli delivered at 10 s intervals,
and volunteers were asked to discriminate between two pain-
ful stimuli intensities (low and high intensity). These levels
were determined as 90% (low) and 110% (high) of the laser
energy (W/cm2) required to produce a pain score of 6 on the
aforementioned 0–10 intensity scale. At the end of each re-
cording block, volunteers were asked to rate the average pain
experience.
The attention variant of paradigm B asked the volunteers to
attend to the pain stimuli. In contrast, during the distraction
task, volunteers were required to divert their attention away
from the laser pain by calculating a series of 2-digit subtrac-
tion problems of varying difficulty (e.g. 71 − 51=, 92 − 27=).
The calculation was displayed on a computer screen for 5 s,
the laser pulse was delivered after 1 s and the volunteer was
required to solve the calculation in the remaining 4 s. The
percentage of correct mathematical solutions and correct rat-
ing of the pain level delivered was calculated.
In order to match tasks visually, the mathematical problem
was presented to the volunteer in both the attention and dis-
traction tasks. During the distraction task, volunteers were
required to perform the subtraction, whereas in the attention
task, volunteers were required to fixate on the screen, whilst
discriminating between the two levels of heat intensity, but not
attempt the calculation.
Plasma tryptophan collection and assay
During visits 2 and 3, blood samples were collected (at time
points 0, +4 and +6 h) in lithium heparin tubes and immedi-
ately centrifuged for 10 min at 2400 rpm/4 °C. Plasma was
isolated and stored at −20 °C before being assayed for total
and free TRP. In addition, the ratio of large nucleotide amino
acids (LNAAs) and TRP was calculated as this is a well-
known measure of the available TRP in the brain for serotonin
synthesis (Fernstrom 1977). Plasma TRP and LNAA concen-
trations were measured by high-performance liquid chroma-
tography with fluorescence end-point detection. The plasma
TRP and LNAA concentrations at time points +4 and +6 h
were averaged within subject to create the ‘post’-drink level.
Psychological assessment
Mood was assessed throughout the two experimental days at
set time points. The Hospital Anxiety and Depression Scale
(HADS) score (Zigmond and Snaith 1983) was completed at
time point 0 h at each visit. A visual analogue scale for de-
pression (VAS; rated on a 100-mm line where 0 mm = none
and 100 mm = extreme; Wewers and Lowe 1990) was com-
pleted at 0, +4 and +6 h. A Profile of Mood State (POMS)
(where increased score correlates to increased depressive
mood disturbance; McNair et al. 1971) questionnaire was also
completed at time points 0, +4 and +6 h. Prior to starting the
study, we were unsure as to which questionnaire would be
more sensitive to changes in mood state; therefore, we select-
ed three questionnaires. All three were reported to avoid se-
lection bias.
Analysis
Statistical analyseswere performed using IBMSPSS Statistics
22 (SPSS Inc., Chicago, IL) and graphs created using
GraphPad Prism (version 7). Statistical analysis for threshold
and tolerance for paradigm A was carried out using repeated
measures analysis of variance (RM-ANOVA) with within-
subject factors: condition (BAL vs. ATD) and pain type
(threshold vs. tolerance). Statistical analysis for paradigm B
was carried out using RM-ANOVAwith the following within-
subject factors: condition (BAL vs. ATD), task (attending vs.
distraction) and pain level (low and high). Furthermore,
Spearman’s rank correlation analysis was carried out to estab-
lish the relationship between the percentage reduction of TRP
levels and experimental output. Non-parametric analysis was
carried out due to negatively skewed data. Statistical analysis
was carried out on the HADS and POMS scores using RM-
ANOVA analysis with within-subject factors: condition (BAL
vs. ATD) and time point (0, 4 and 6 h). The correct ratings of
the stimuli (sensory discrimination) were analysed using a
RM-ANOVA with within-subject factors: condition (BAL
vs. ATD) and pain level (low vs. high), and correct number
of calculations during paradigm B were analysed using a two-
tailed paired samples t test. Significance was considered at
p < 0.05 and data was expressed as mean ± SD.
Results
Plasma tryptophan
Plasma TRP levels were significantly lower following the
consumption of the ATD in comparison to the BAL drink.
Before administration of the drinks, TRP levels were not sig-
nificantly different across both conditions (BAL vs. ATD at
0 h; 57.35 ± 11.70 vs. 58.46 ± 6.49, p = 0.7). Post-drink, ATD
significantly reduced plasma TRP levels (BAL vs. ATD;
94.20 ± 38.91 vs. 19.84 ± 4.36 nmol/m; p < 0.001; Fig. 1).
In comparison to pre-drink levels of TRP, ATD effectively
reduced total plasma TRP levels by 65.05 ± 7.29%, and the
ratio of TRP to large neutral amino acids (TRP:LNAA) de-
creased by 53.8 ± 28.52% (from 0.16 ± 0.06 to 0.06 ± 0.04). In
contrast, under control conditions (BAL), total TRP levels
increased from pre-drink concentration by 67.28 ± 10.42%,
and the ratio of TRP:LNAA increased by 85.0 ± 19.29%
(from 0.21 ± 0.11 to 0.32 ± 0.21) (Fig. 1). The post-drink
concentration of TRP (nmol/ml) was reported to be
94.20 ± 38.9 nmol/ml for BAL and 19.84 ± 4.4 nmol/ml for
ATD (mean ± SD) indicating a 74.61 ± 13.4% difference post-
drink. There was no effect of order of the condition (i.e. ad-
ministration of ATD drink on visit 2 or 3) on the change in
TRP levels or LNAA:TRP ratio.
ATD and questionnaire measures
There were no effects of condition (BAL vs. ATD) on any of
the mood scores. The participants’ initial mood prior to each
experiment (0 h), recorded by HADS scores, did not differ
between conditions or time point (BAL vs. ATD;
5.13 ± 3.37 vs. 4.93 ± 3.06; p = 0.68).). Additionally, the
POMS scores and depression VAS scores (mm) recorded at
0, 4 and 6 h showed no statistical difference for condition,
time point, nor interaction between conditions (BAL and
ATD) and time points (0, 4, 6 h) (see Table 1).
Paradigm A: pain threshold and tolerance using contact
thermode
A RM-ANOVA reported a significant effect of condition
(BAL vs. ATD) (F = 7.111, p = 0.019), such that ATD led to
a reduced threshold and tolerance to thermode temperature.
The threshold and tolerance temperature was higher in the
BAL condition (threshold 44.00 ± 3.06 °C, tolerance
48.87 ± 2.00 °C) in comparison to the ATD condition (thresh-
old 43.03 ± 2.77 °C, tolerance 47.73 ± 1.86 °C) (Fig. 2). There
was no effect of order (F = 0.428, p = 0.524). There was no
significant condition * pain type interaction (F = 0.001,
p = 0.979) indicating that the temperature for threshold and
tolerance was affected in the same way by the ATD condition.
Correlation analysis
For the correlation analysis for each participant, a percentage
difference was calculated of the post-drink TRP concentration
(nmol/ml) after the ATD drink in comparison to post-BAL
drink (−75.61 ± 13.40%) (mean ± SD). Given that ATD sig-
nificantly reduced both threshold and tolerance temperatures,
hence, an average thermode temperature was calculated per
participant [(threshold + tolerance)/2] (group mean BAL
46.43 ± 43 °C, ATD 45.38 ± 2.23 °C) (mean ± SD) and the
percentage difference in temperature between BAL and ATD
post-drink calculated for each participant (group mean
2.21 ± 3.31%) (mean ± SD). Spearman’s rank correlation
analysis showed a positive correlation between the difference
of TRP level and the degree of change in the thermode tem-
perature, rs(13) = 0.548, p < 0.005 (Fig. 3).
Fig. 1 The change in TRP levels and the LNAA/TRP ratio pre- and post-
depletion drink measured from blood samples at 0 h (pre) and average of
4 and 6 h (post). (Left) The average TRP level at 0 h was 57.35 ± 11.70 vs.
58.46 ± 6.49 nmol/ml for BAL and ATD conditions, respectively, which
reported no significant difference (p = 0.7). The average TRP level post-
drink was 94.20 ± 38.91 vs. 19.84 ± 4.36 nmol/ml for BAL and ATD
conditions, respectively, with statistical difference (p < 0.001). (Right)
The average LNAA:TRP ratio at 0 h was 0.21 ± 0.11 vs. 0.16 ± 0.06
for BAL and ATD, respectively. Post-drink, the LNAA:TRP ratio was
reported as 0.32 ± 0,21 vs. 0.06 ± 0,04 for BAL and ATD, respectively,
with a statistically significant difference (p = <0.001). Black: BAL drink,
white: ATD drink. Mean ± SD, n = 15, ***p < 0.001
Paradigm B: attention and distraction
CO2 laser pain scoring
The energy of the laser stimuli (W/cm2) administered at 90%
(BAL 7.18 ± 1.81 to ATD 6.80 ± 1.87) or 110% (BAL
9.01 ± 2.19 to ATD 8.53 ± 2.16) of high pain was not signif-
icantly different between BAL and ATD conditions.
Attention and distraction paradigm
Within-subject RM-ANOVA was conducted to compare the
effect of condition (BAL and ATD) and task (attention and
distraction) on the rating of the low- and high-laser stimuli.
The overall pain ratings of low and high stimuli during both
tasks were not significantly affected by the ATD condition
(low: F = 0.33, p = 0.574; high: F = 3.663, p = 0.078).
However, the high-laser stimuli did show a trend to signifi-
cance (p = 0.078) such that the ATD resulted in an increase in
pain ratings across both tasks, suggesting a slight increased
sensitivity to the laser stimuli. Secondly, there was an effect of
task such that pain ratings were lower during distraction com-
pared to no distraction; for the low-laser intensity, this was a
trend reduction (F = 4.046, p = 0.065), whereas for the high-
laser stimuli, it was significant (F = 12.893, p = 0.003). There
were no interactions between condition and task for low-
(F = 0.571, p = 0.463) or high- (F = 0.875, p = 0.315) laser
stimuli, indicating that the condition of the participant did not
alter the effect of task-induced changes on pain rating (Fig. 4).
Cognitive performance
The ability to discriminate high- and low-intensity laser stimuli
was calculated during paradigm 2 with a RM-ANOVA with
within-subject factors: condition (BAL vs. ATD) and pain level
(low vs. high). The condition * pain level interaction was sig-
nificant (F = 7.28, p = 0.018) with participants significantly
more likely to incorrectly rate low-intensity stimuli as high
intensity under ATD conditions in comparison to BAL.
Table 1 The scores for POMS and depression VAS (mm) are reported for both conditions (BAL and ATD) for three time points (0, 4 and 6 h). A
repeated measures (RM) ANOVA reported no statistical significant interaction between condition and time point for either POMS or VAS scores
Time RM ANOVA condition * time point
0 h 4 h 6 h
POMS BAL 4.27 ± 3.77 4.67 ± 3.04 3.40 ± 2.72 F = 0.523, p = 0.599
ATD 4.33 ± 3.70 3.87 ± 3.80 4.13 ± 4.34
VAS (/100 mm) BAL 5.73 ± 8.59 7.93 ± 10.25 6.80 ± 8.44 F = 1.248, p = 0.303
ATD 4.26 ± 5.56 4.86 ± 5.07 6.93 ± 8.14
Fig. 2 The mean thermode threshold and tolerance temperature plotted
for all participants under BAL and ATD conditions. The threshold and
tolerance of the thermode during the ATD condition were significantly
reduced in comparison to the BAL condition (F = 7.111, p = 0.019). The
y-axis is restricted to the minimum (32 °C) and maximum (52 °C) of the
thermode temperature (n = 15, mean + SD)
Fig. 3 Correlation analysis comparing the post-drink difference in TRP
(nmol/ml) for BAL and ATD and the average thermode temperature
change for BAL to ATD. A significant positive correlation was reported
via a Spearman’s rank correlation analysis, rs(13) = 0.548, p < 0.005,
hence indicative that a higher decrease in TRP concentration correlates
to a higher decrease in thermode temperature. A line of best fit is shown,
N = 15
The percentage correct calculations during the distraction
task of paradigm B were compared between BAL and ATD
conditions by a two-tailed paired samples t test. The statistical
analysis showed a significant reduction (p = 0.039) in correct
calculations during distraction under the ATD condition.
Discussion
The present study examined the role of 5-HT in human pain
processing by depleting plasma TRP concentrations in healthy
volunteers via ATD. Blood analysis indicated a significant
reduction in total plasma TRP levels and the LNAA ratio
which was consistent with previous findings (Gallagher
et al. 2003; van der Veen et al. 2007). The LNAAs and TRP
compete for uptake into the brain, and hence, the LNAA ratio
was calculated to establish the degree to which TRP levels
have decreased within the brain. Therefore, alongside the re-
duction in the TRP concentration in the blood plasma, the
decline in the LNAA/TRP ratio reinforces that serotonin syn-
thesis within the brain has been reduced via the ATD drink and
repletion via the BAL drink. The observable rise in TRP levels
under control conditions (BAL) is due to TRP repletion and is
consistent with previous findings (Gallagher et al. 2003).
First of all, the analysis of the HADS and POMS question-
naires showed no significant difference between conditions
(BAL vs. ATD), and hence, a dissociation between mood
and the findings regarding pain perception can be made.
This also supports the use of a strict exclusion criteria
preventing the recruitment of participants whom are suscepti-
ble to 5-HT-induced mood changes (Benkelfat et al. 1994;
Delgado et al. 1990; Moore et al. 2000; Hughes et al. 2003;
Klaassen et al. 1999).
Paradigm A: thermode threshold and tolerance
An interesting finding of this study was the significant reduc-
tion in the participants’ threshold and tolerance level of the
heat thermode during ATD condition. To the best of our
knowledge, this is the first time that this relationship has been
reported, and indicates that TRP depletion results in an in-
creased sensitivity to heat pain. Previous studies have
highlighted how increasing the level of TRP within the brain
causes a reduced sensitivity to pain (Seltzer et al. 1982), and
hence, this study has reported the corresponding opposing
effect as decreasing TRP levels has increased pain sensitivity.
Furthermore, the pain tolerance of an individual could be
said to have a motivational component, and there has been
research exploring the role of 5-HT in motivation and
resilience. For instance, Robinson et al. (2012) used aversive
stimuli such as monetary loss or sad faces to demonstrate that
ATD enhanced punishment prediction and lowered resilience,
whereas a higher level of TRP correlated with a lower punish-
ment prediction and potentially a higher level of resilience to
affective disorders. Therefore, the role of 5-HT in resilience
may explain the results found in this study whereby ATD re-
duced pain tolerance, possibly via lowered resilience. However,
to the best of our knowledge, there has not been any research
outlining the role of 5-HT in the resilience of pain stimuli rather
than monetary loss or sad faces prior to this study.
The decreased levels of TRP, and hence 5-HT, resulting in
the sensitisation of the thermode-induced pain suggest that the
serotonergic descending spinal-raphe projections have been
altered. The action of 5-HT within this network can both in-
hibit and facilitate pain, and the outcome depends strongly on
the type of 5-HT receptor subtype that is activated, such that
anti-nociception is associated with activation of 5-HT1A, 5-
Fig. 4 The effect of attention and distraction (task) on the pain rating for
low (left) and high (right) laser-induced pain. (Left) A plot of the average
pain rating participants gave for low-laser intensity during both task
states. BAL or ATD condition did not report any significant difference
in ratings of low pain (F = 0.33, p = 0.574). Distraction did not signifi-
cantly reduce the rating of low pain in either condition; however, a trend
was reported such that ATD caused an increase in pain ratings (F = 4.046,
p = 0.065). There were no effects of condition on task pain ratings of low-
laser intensity (F = 0.571, p = 0.463). (Right) A graph of the average pain
rating participants gave for high-laser stimuli during the task states under
both conditions. A significant reduction in pain rating of the high-laser
stimuli was reported during distraction for both BAL and ATD conditions
(F = 12.893, p = 0.003), yet no significant interaction of condition and
task was reported (F = 0.875, p = 0.315). Hence, ATD did not affect the
task-induced changes in pain ratings. n = 15, mean ± SD, **p < 0.01.
Although not significant, a trend was shown for the pain rating under
ATD conditions being slightly higher in the distraction task in comparison
to the BAL condition (F = 3.663, p = 0.078)
HT1B, 5-HT1D and 5-HT7 subtypes, whilst activation of 5-
HT2A and 5-HT3 is associated with pro-nociception
(Ossipov et al. 2014). This study has shown that a global
reduction in 5-HT results in sensitisation of pain and thus
suggests that the activation of the anti-nociceptive receptor
subtypes is reduced more than the pro-nociceptive receptor
subtypes. The distribution of the anti-nociceptive receptor
subtypes is widespread with high concentrations of 5-HT1A/
1B in the raphe nucleus and basal ganglia, whilst the pro-
nociceptive 5-HT receptor subtypes are more prominent in
the neocortex and not in the raphe nucleus (Burnet et al.
1995). Therefore, as the paradigm does not necessarily depend
strongly on cognition via the higher cortical regions, it would
be possible that the spinal-raphe projections and basal ganglia
processing are more important in the processing of the thresh-
old and tolerance responses to the thermode, and could ex-
plain whyATD resulted in sensitisation of pain response to the
thermode. This could also explain why there was no signifi-
cant effect seen in the CO2 laser attention paradigm.
The correlation analysis of TRP levels highlighted the
quantitative relationship between the level of TRP depletion
and changes in pain perception. This further strengthens that
the concentration of 5-HT is related to the perception of pain.
Furthermore, the fact that an acute decrease in 5-HT elicits a
decrease of pain perception suggests that a persistent decrease
of 5-HT over time could elicit a larger change in pain percep-
tion, which could be clinically presented as chronic pain. The
long-term depletion of 5-HT may also play a part in the mal-
adaptive neuroplastic changes that occur in the brain in chron-
ic pain conditions. Low levels of 5-HT have been correlated
with chronic pain disorders such as FM (Alnigenis and
Barland 2001); however, results are variable possibly due to
cerebrospinal fluid (CSF) providing a relatively indirect indi-
cation of changes in brain chemistry that is very dependent on
CSF dynamics. In addition, it is widely known that a persistent
reduction of 5-HT is linked with depression and anxiety dis-
orders (Shopsin and Frank Feiner 1984), which have also been
linked to the exacerbation and persistence of chronic pain
(Jones and Brown 2017).
Paradigm B: attention and distraction
Paradigm B investigated the use of laser stimuli and how the
participant’s attentional state impacts pain perception. The in-
vestigation supported prior knowledge that distraction reduces
the intensity of pain perceived (Boyle et al. 2008; Bantick
et al. 2002; de Tommaso et al. 2008; Miron et al. 1989;
Petrovic et al. 2000; Rémy et al. 2003; Tracey et al. 2002);
however, this effect was only reported to be significant for
high pain. Paradigm B was minimally affected by ATD such
that there were no ATD-induced change in psychophysics or
the distraction paradigm pain ratings. However, although not
significant and only a trend was reported, it is interesting to
note that ATD appeared to slightly increase the rating of high
pain across both tasks. This would support the findings seen in
paradigm A that 5-HT depletion results in sensitisation of
pain. Nevertheless, paradigm B indicated that the
distraction-induced analgesia was not altered by the acute de-
pletion of 5-HT. Further investigation would be interesting to
explore whether chronic depletion in TRP could elicit a stron-
ger effect in the sensitisation of laser-evoked pain stimuli.
Nonetheless, previous research supports the notion that se-
rotonin is involved in pain distraction. For instance, distrac-
tion analgesia coincides with increased activity within the
posterior thalamus and PAG structures, as well as altered ac-
tivity in pain matrix regions such as the insula cortex, the
somatosensory cortices and the anterior cingulate cortex
(ACC) (Bantick et al. 2002; Dunckley et al. 2007;
Frankenstein et al. 2001). These aforementioned regions are
all, directly or indirectly, potentially influenced by serotoner-
gic activity (Ford et al. 2008; Lechin et al. 2005; Oke et al.
1997). Hence, it would be predicted that ATD could impact
the typical function within these sites and result in an impaired
distraction-induced analgesia. The reason that we have not
seen any significant alteration in the distraction paradigm
could be due to the short duration of the depletion or experi-
mental design. For instance, the mathematical task was pre-
sented to the participant in both conditions to maintain a con-
sistent visual fixation; however, this may have resulted in
participants completing the mathematical questions uninten-
tionally and diminishing the contrast between the distraction
task results. Therefore, a modification of the current paradigm
or an alteration in the type of distraction, such as auditory or a
more complex task, could elicit a different outcome.
Paradigm B: cognitive performance
Serotonergic neurotransmission is associated with general
cognitive ability (Schmitt et al. 2006). We found that ATD
impacted on cognitive and executive function during sensory
discrimination and mathematical tasks. Following ATD, par-
ticipants were poorer at discriminating between low- and
high-pain stimulation. This highlights that cognitive process-
ing may have been altered via the ATD. The significant de-
crease in the percentage correct calculations also highlights an
impaired or altered level of cognition due to the ATD. These
findings could be explained by serotonergic modulation of
insula and somatosensory cortices which both receive seroto-
nergic input as discussed in the preceding section.
Methodological considerations
It is important to highlight that the small sample size of this
study is a methodological limitation and further studies are
required to confirm the reported findings.
Relevance to current methods of treating pain disorders
There are numerous studies highlighting the use of SSRIs to treat
chronic pain; however, the specific mechanism of its action is not
completely understood and variation in effectiveness is well doc-
umented (Mika et al. 2013; McQuay et al. 1996). This study
shows that 5-HT in humans has a potentially direct role in pain
processing as we have successfully dissociated the effects from
mood changes. The significant increase in sensitivity of the
thermode temperature in this study implies that an increased level
of 5-HT via the use of SSRIs would reverse the sensitivity seen
due to low 5-HT. Additionally, the correlation analysis has indi-
cated that the concentration of TRP, and thus 5-HT, is positively
correlated to pain perception. The lack of difference seen in par-
adigm B, which involved both a different pain stimuli and cogni-
tive demand, may help to explain the variability seen in the effec-
tiveness of SSRIs used for chronic pain. The role of serotonin in
pain is yet to be clearly defined and thus is likely to have multiple
roles in pain processing. The findings in the current study could
be explained on the basis of modulation of both the non-cognitive
diffuse noxious inhibitory controls (DNIC) and cognitive compo-
nents of nociceptive processing. Both of these could increase the
resilience to pain in different ways. Recent studies have demon-
strated a compensatory upregulation of opiate receptor binding in
the brain in response to chronic pain that also correlates with
increased pain resilience (increased pain tolerance) (Brown et al.
2008). The paper of Abbott and Young (1988) finding TRP de-
pletion blocking opiate analgesia in humans suggests that both
systems may be important modulators of pain resilience. The size
of the effects on pain threshold and tolerance is, however, quite
modest which is in keeping with the quite modest effect size seen
in clinical pain studies of SSRIs. Therefore, the effectiveness of
the SSRIs may depend on the type of chronic pain and individual
cognitive and non-cognitive differences between patients. We
should therefore probably not raise our expectations of the thera-
peutic effects of manipulation of this system on its own toomuch,
but learn how individuals can best benefit from this without suf-
fering untoward side effects. One possibility for the future, in
relation to Seltzer et al. (1982), is potentially to prevent chronic
pain by dietary supplementation by increasing the resilience of
those at risk of chronic pain. This study has clearly shown that 5-
HT has a role inmodulating pain perception that is independent of
mood state, and therefore, this study supports the beneficial use of
SSRIs for treatment of chronic pain.
However, there is much debate regarding the involvement
of 5-HTs in pain perception, and it is clearly not a one-
directional relationship. 5-HT has been linked to several
chronic pain conditions. However, the specific role of seroto-
nin in chronic pain is conflicting such that low serotonin levels
have been associated with fibromyalgia (Wolfe et al. 1997)
whilst high serotonin has been linked to CRPS (Wesseldijk
et al. 2008). In addition, there is evidence that neurodegener-
ation of serotonergic regions in Parkinson’s disease patients
results in the development of chronic pain due to compro-
mised descending pain pathways (Millan 2002; Hornung
2003; Braak et al. 2003; Halliday et al. 1990). The difference
could be explained by the variance in the action of the 5-HT
receptor subtypes, and a study has highlighted that both ago-
nists and antagonists of specific receptor 5-HT subtypes are
promising therapeutic targets (Bardin 2011).
Furthermore, a meta-analysis (McQuay and Moore 1997;
McQuay et al. 1996) suggests that less specific tricyclic anti-
depressants (TCAs) and dual (5-HT and norepinephrine) re-
uptake inhibitors serotonin-norepinephrine reuptake inhibitors
(SNRIs) are more effective in the treatment of pain. However,
due to the negative side effects associated with TCAs, the
most effective and safe serotonin-modulating analgesic ap-
pears to be SNRIs (Stahl et al. 2005). The effectiveness of
TCAs and SNRIs suggests that the combined increase in both
5-HT and noradrenaline (NA) may be the most effective form
of analgesia. As we know very little about the effects of NA on
human nociceptive processing, this may be a relevant focus
for future studies.
Conclusion
In conclusion, this study has indicated a connection between
the reduction of global 5-HT via ATD and an alteration of pain
perception whilst dissociating these findings from altered
mood state. The ATD significantly reduced both threshold
and tolerance of the thermode temperature, demonstrating a
clear role of 5-HT in pain perception. ATD did not significant-
ly affect distraction-induced analgesia but did affect cognitive
appraisal of the sensory-discriminatory aspects of pain. The
study supports the understanding that low levels of 5-HT cor-
relate to pain sensitisation and help to understand possible
mechanisms of chronic pain states. It also helps to explain
the variable effectiveness seen in the use of SSRIs for chronic
pain. Future studies on 5-HT’s role in the cognitive and non-
cognitive aspects of pain processing and chronic pain will be
important to improve individual treatment choice for patients
with chronic pain.
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